TFF Pharmaceuticals Receives Approval from Health Canada to Enter Human Clinical Trials for Inhaled Formulation of Niclosamide to Treat COVID-19

~ First Patient in Phase 1 Trial to be Dosed in November with Enrollment Completion Anticipated by Early Q1 2022 ~ Preclinical Studies of Inhaled Dry Powder Formulation of Niclosamide Showed a Seven-Fold Reduction in Lung Viral Load in Hamsters When Administered 24 Hours After Inoculation with SARS-CoV-2

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here